Burden and treatment of chronic obstructive pulmonary disease among people using illicit opioids: matched cohort study in England

Changing age profile and incidence of injecting drug use initiation among people in Australia who inject drugs: evidence from two national repeated cross-sectional studies

Background

The age of people who inject drugs appears to be increasing in some high-income countries. We aimed to explore trends in the age of people injecting and recently starting to inject drugs in Australia, and to model incidence of initiation over time.

Methods

We obtained data from the Illicit Drug Reporting System (IDRS) and the Australian Needle Syringe Program Survey (ANSPS), which comprise annual cross-sectional surveys with people who inject drugs (2000-2019). Outcome measures were current age, age of initiation, and time since initiation (both surveys), and drug first injected (IDRS only). We estimated time trends in age using quantile regression. We used the relative number of people initiating injecting drug use each year and existing population size estimates to model incidence of initiation.

Findings

In total, 58,465 interviews with people who reported injecting drugs in the past month (33.7% women) were included. In both surveys, the median age increased over the study period (IDRS: 28-43 years; ANSPS 28-44 years). The median time since initiation also increased over the study period (IDRS: 8-22.5 years; ANSPS: 9-24 years), and the median age of initiation increased with calendar year of initiation (IDRS: 18-34 years; ANSPS: 20-30 years). Women tended to be younger and commence injecting drug use at a younger age than men. Modelling suggested that similar numbers of people injected drugs for the first time each year from 1980 (national estimates of 15,570 and 17,020 new initiates using IDRS and ANSPS data, respectively) to 1996 (IDRS: 16,360; ANSPS: 22,300 new initiates), followed by a decisive decline in incidence until 2012 (IDRS: 1110; ANSPS: 1830), whereafter it has fluctuated but remained low. Meth/amphetamine was consistently the predominant drug injected at initiation among IDRS participants, although there were peaks in heroin as the drug injected at initiation in the early 1980s and mid-1990s.

Interpretation

In 2019, most people who were injecting drugs in Australia were part of a cohort that began injecting in the 1980s or 1990s. Consequently, the population was older and had been injecting drugs for longer compared to those injecting drugs in 2000. This has implications for health service delivery to people who inject drugs, with increasing age likely to be accompanied by a rise in chronic health conditions and an increase in injecting duration potentially resulting in higher incidence of injecting-related injuries and diseases.

Funding

Australian Government Department of Health and Aged Care.

Evaluation of E-Cigarette Use in Opioid-Dependent Patients in Maintenance Treatment

INTRODUCTION

As tobacco smoking decreases, the use of e-cigarettes is on the rise. There is a debate whether switching from smoking to the use of e-cigarettes might represent a harm reduction strategy for those who smoke tobacco heavily, a habit often observed in individuals with opioid dependence. The present study investigated the prevalence and patterns of tobacco smoking and e-cigarette use in patients in opioid maintenance treatment (OMT) and whether e-cigarette use contributed to the cessation of smoking tobacco.

METHODS

In 2014 (n=84) and in 2021 (n=128), patients from two OMT clinics of a psychiatric university hospital were interviewed RESULTS: In both surveys, patients presented with a comparable average age (45.6 vs. 46.9 years of age), gender distribution (mainly male 71.4 vs. 75.8%), and length of OMT history (median: 66 vs. 55 months). The lifetime prevalence of e-cigarette use (45.2% in 2014 and 38.3% in 2021) was much higher than the current prevalence (4.9% and 7.8%, respectively). Few patients reported either a complete switch from smoking to the use of e-cigarettes (2014, n=1 vs. 2021, n=2) or the achievement of abstinence from smoking after a temporary use of e-cigarettes (2014, n=2 vs. 2021, n=1).

DISCUSSION

No increase in the use of e-cigarettes was observed in these groups of patients undergoing OMT. Presumably, harm reduction strategies relating to the use of e-cigarettes in this group need to be supported by motivational interventions. Given the high morbidity and mortality due to smoking, OMT clinics should offer professional help in reducing smoking.

Improving access to pulmonary rehabilitation for patients with COPD treated for substance misuse in the London Borough of Islington

Chronic obstructive pulmonary disease (COPD) is a collection of conditions that cause permanent damage to the lungs. Among a range of treatment options, patients can benefit from pulmonary rehabilitation (PR) programmes involving physical exercises and education.The risk of developing COPD is higher for substance misusers than the general population. Substance misusers with COPD have more severe symptoms and poorer health outcomes than other COPD patients, and experience inequalities in accessing PR services.This project aimed to work with a local substance misuse service to increase the referrals of patients with COPD with a history of drug and/or alcohol problems to a PR programme in the London Borough of Islington. Quality improvement methods were used to explore barriers to accessing PR and to identify ways of making referral to PR easier. A series of change ideas were implemented and tested sequentially through plan-do-study-act, including updating referral systems, educating staff and improving access to diagnosis.The primary objective was to achieve 100 eligible referrals during the 14-month project period. In practice, a total of 57 patients were referred to the programme. Sustained engagement with patients was challenging, with significant attrition observed from referral to programme completion. However, there was indicative evidence of clinical improvements in dyspnoea and exercise capacity among PR completers and qualitative feedback of improved health and well-being.Although referrals numbers were less than expected, we have established an innovative respiratory care pathway for substance misusers, founded on a holistic approach to diagnosis and treatment. There are also clear pointers as to how this approach can be sustained and developed further to maximise the benefits for this cohort of patients.

Health-care resource use among patients who use illicit opioids in England, 2010-20: A descriptive matched cohort study

BACKGROUND AND AIMS

People who use illicit opioids have higher mortality and morbidity than the general population. Limited quantitative research has investigated how this population engages with health-care, particularly regarding planned and primary care. We aimed to measure health-care use among patients with a history of illicit opioid use in England across five settings: general practice (GP), hospital outpatient care, emergency departments, emergency hospital admissions and elective hospital admissions.

DESIGN

This was a matched cohort study using Clinical Practice Research Datalink and Hospital Episode Statistics.

SETTING

Primary and secondary care practices in England took part in the study.

PARTICIPANTS

A total of 57 421 patients with a history of illicit opioid use were identified by GPs between 2010 and 2020, and 172 263 patients with no recorded history of illicit opioid use matched by age, sex and practice.

MEASUREMENTS

We estimated the rate (events per unit of time) of attendance and used quasi-Poisson regression (unadjusted and adjusted) to estimate rate ratios between groups. We also compared rates of planned and unplanned hospital admissions for diagnoses and calculated excess admissions and rate ratios between groups.

FINDINGS

A history of using illicit opioids was associated with higher rates of health-care use in all settings. Rate ratios for those with a history of using illicit opioids relative to those without were 2.38 [95% confidence interval (CI) = 2.36-2.41] for GP; 1.99 (95% CI = 1.94-2.03) for hospital outpatient visits; 2.80 (95% CI = 2.73-2.87) for emergency department visits; 4.98 (95% CI = 4.82-5.14) for emergency hospital admissions; and 1.76 (95% CI = 1.60-1.94) for elective hospital admissions. For emergency hospital admissions, diagnoses with the most excess admissions were drug-related and respiratory conditions, and those with the highest rate ratios were personality and behaviour (25.5, 95% CI = 23.5-27.6), drug-related (21.2, 95% CI = 20.1-21.6) and chronic obstructive pulmonary disease (19.4, 95% CI = 18.7-20.2).

CONCLUSIONS

Patients who use illicit opioids in England appear to access health services more often than people of the same age and sex who do not use illicit opioids among a wide range of health-care settings. The difference is especially large for emergency care, which probably reflects both episodic illness and decompensation of long-term conditions.

Safe inhalation pipe provision (SIPP): protocol for a mixed-method evaluation of an intervention to improve health outcomes and service engagement among people who use crack cocaine in England

BACKGROUND

Over 180,000 people use crack cocaine in England, yet provision of smoking equipment to support safer crack use is prohibited under UK law. Pipes used for crack cocaine smoking are often homemade and/or in short supply, leading to pipe sharing and injuries from use of unsafe materials. This increases risk of viral infection and respiratory harm among a marginalised underserved population. International evaluations suggest crack pipe supply leads to sustained reductions in pipe sharing and use of homemade equipment; increased health risk awareness; improved service access; reduction in injecting and crack-related health problems. In this paper, we introduce the protocol for the NIHR-funded SIPP (Safe inhalation pipe provision) project and discuss implications for impact.

METHODS

The SIPP study will develop, implement and evaluate a crack smoking equipment and training intervention to be distributed through peer networks and specialist drug services in England. Study components comprise: (1) peer-network capacity building and co-production; (2) a pre- and post-intervention survey at intervention and non-equivalent control sites; (3) a mixed-method process evaluation; and (4) an economic evaluation. Participant eligibility criteria are use of crack within the past 28 days, with a survey sample of ~ 740 for each impact evaluation survey point and ~ 40 for qualitative process evaluation interviews. Our primary outcome measure is pipe sharing within the past 28 days, with secondary outcomes pertaining to use of homemade pipes, service engagement, injecting practice and acute health harms.

ANTICIPATED IMPACT

SIPP aims to reduce crack use risk practices and associated health harms; including through increasing crack harm reduction awareness among service providers and peers. Implementation has only been possible with local police approvals. Our goal is to generate an evidence base to inform review of the legislation prohibiting crack pipe supply in the UK. This holds potential to transform harm reduction service provision and engagement nationally.

CONCLUSION

People who smoke crack cocaine in England currently have little reason to engage with harm reduction and drug services. Little is known about this growing population. This study will provide insight into population characteristics, unmet need and the case for legislative reform.

TRIAL REGISTRATION

ISRCTN12541454  https://doi.org/10.1186/ISRCTN12541454.

[Bronchial diseases and heroin use. A systematic review]

INTRODUCTION

Heroin use can cause respiratory complications including asthma, chronic obstructive pulmonary disease (COPD) and bronchiectasis (BD).

OBJECTIVES

A general review of the literature presenting the data on the relationships between heroin consumption and bronchial complications, while underlining the difficulties of diagnosis and management.

DOCUMENTARY SOURCES

Medline, 1980-2022, keywords "asthma" or "bronchospasm" or "COPD" or "bronchiectasis" and "heroin" or "opiate" or "opiates", with limits pertaining to "Title/Abstract". Concerning asthma, 26 studies were included, as were 16 for COPD and 5 for BD.

RESULTS

Asthma and COPD are more prevalent among heroin addicts, who are less compliant than other patients with their treatment. The authors found a positive association between frequency of asthma exacerbations, admission to intensive care and heroin inhalation. Late diagnosis of COPD worsens the course of the disease; emphysema and BD are poor prognostic factors.

CONCLUSION

Bronchial diseases in heroin users can be identified by means of respiratory function exploration and chest CT scans. These tests should be performed frequently in view of optimizing their care, which includes their weaning themselves from addictive substances.